Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

HYMPAVZI® (Marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Summary by The Huntsville Item
NEW YORK--(BUSINESS WIRE)--Dec 6, 2025-

4 Articles

The Huntsville ItemThe Huntsville Item
+2 Reposted by 2 other sources
Lean Left

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

NEW YORK--(BUSINESS WIRE)--Dec 6, 2025-

Read Full Article
stocktitan.netstocktitan.net

Pfizer (NYSE: PFE) reports HYMPAVZI Phase 3 data showing 93% bleed reduction vs on-demand care

Phase 3 BASIS trial in hemophilia A/B with inhibitors found HYMPAVZI cut mean treated bleeds 93% vs on-demand care and improved key quality-of-life scores.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news in on Saturday, December 6, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Pfizer icon

Pfizer

New York City icon

New York City

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal